Rare cases of possible materno-fetal transmission of cancer have been recorded over the past 100 years but evidence for a shared cancer clone has been very limited. We provide genetic evidence for mother to offspring transmission, in utero, of a leukemic cell clone. Maternal and infant cancer clones shared the same unique BCR-ABL1 genomic fusion sequence, indicating a shared, single-cell origin. Microsatellite markers in the infant cancer were all of maternal origin. Additionally, the infant, maternally-derived cancer cells had a major deletion on one copy of chromosome 6p that included deletion of HLA alleles that were not inherited by the infant (i.e., foreign to the infant), suggesting a possible mechanism for immune evasion.
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fetus ͉ fusion gene ͉ leukemia R are cases of melanoma or hemopoietic malignancies in infants have been recorded that may have been of maternal origin (1) . Genetic evidence for a shared, materno-fetal clone of cancer cells has, however, to date, been sparse and based upon limited karotype information (1) . Unambiguous attribution of transmission of a cancer clone should be achievable by genetic fingerprinting, the most striking precedent for which is canine transmissible venereal sarcoma (CTVS) in which multiple cases worldwide derive from a single clone (2) . Leukemia fusion genes, generated by chromosome translocations, have patient-specific or idiosyncratic genomic sequences at the fusion breakpoints and are frequently early or initiating events (3) . They therefore provide stable, specific, and sensitive clonal markers and can unambiguously identify a single-cell origin in different individuals as documented with monozygotic twins with concordant leukemia (4). We report here equivalent genetic scrutiny of a case of concordant maternal and infant ALL/lymphoma with the BCR-ABL1 fusion gene.
Results
The Mother. The Japanese mother was 28 years old at her child's delivery. No hematological abnormalities had been identified during the pregnancy, and the birth was uncomplicated. Thirtysix days after the delivery, the mother experienced vaginal bleeding. On day 39, she developed fever, and on day 43, bleeding became uncontrollable. Blood showed leukocytosis (206,800/L) with 97% lymphoblasts, anemia (hemoglobin level: 3.5g/dL), and thrombocytopenia (platelet count: 0.2 ϫ 10 4 /L). Bone marrow aspiration revealed peroxidase-negative lymphoblasts (99.6% of nucleated cells), which were positive for CD10, CD19, CD20, CD34, TdT, and CD79a. Chromosomal G-banding showed 46,XX,t (9, 22)(q34;q11), and 3.2 ϫ 10 5 copies/gRNA of p190-type BCR-ABL1 mRNA were detected by RT-PCR. She was diagnosed as having B-cell precursor Phϩ ALL (see SI Text for clinical treatment).
The Infant. The 11-month-old female offspring of the above mother was admitted to hospital with right cheek swelling. MRI revealed a mass in the cheek (Fig. S1 A) and a pleural effusion of the lung. There was no lymph node swelling or organomegaly. She was born with normal delivery at 40 weeks, 5 days gestation. There was no history of prenatal abnormalities including intrauterine growth retardation, and she showed normal growth and development until admission.
Laboratory Findings on Infant Samples. Laboratory analyses of the maternal and infant samples was carried out with full ethical approval in accordance with the Declaration of Helsinki (Local ethics approval # CCR2285) and with informed consent of the family (father). Biopsy of the primary jaw tumor showed the presence of small round blue cell tumor with large nucleus/ cytoplasm ratio, which diffusely proliferated with partial hyalinization of stroma. A large antibody panel was used to distinguish a sarcoma from lymphoma. LCA, CD10, CD20, CD79a, TdT, CD34, and MIC2 were positive by immunohistochemical staining, and CD3, CD5, CD56, desmin, HHF35, S100, GFAP, chromogranin, and synaptophysin were all negative. No cytogenetic analysis was performed but subsequent FISH analysis revealed positivity for the BCR-ABL1 gene (Fig. S1B) .
Cells (48.2%) in the pleural fluid were positive for CD10, CD19, CD34, and HLA-DR and p190-type BCR-ABL1 chimeric mRNA was detected (9.5 ϫ 10 4 copies/gRNA) by quantitative RT-PCR (Q-PCR).
Blood count findings on the infant were as follows; WBC 10,100/L (segment forms 22%; lymphocytes 72%; monocytes 5%; eosinophil 1%), hemoglobin level 12. 2 M.G. and S.M. contributed equally to this work. 3 To whom correspondence may be addressed. E-mail: mel.greaves@icr.ac.uk or skkm12@gmail.com.
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BCR-ABL1 Genomic Fusion Sequencing. We first cloned the BCR-ABL1 genomic breakpoint region from the infant's pleural effusion (PE) (see Materials and Methods). DNA was Whole
Genome Amplified (GenomiPhi, GE Healthcare), according to the manufacturer's instructions. The breakpoint was designated as a fusion between BCR intron 1 (46110 bp from ATG: NM004327) and ABL1 intron 1 (118930 bp from ATG: NM007313) (Fig. 1C) .
DNA from the mother's bone marrow was isolated by scraping cells from a formalin fixed paraffin embedded (FFPE) biopsy slide (the only sample available) using Recoverall (Ambion) as suggested by the manufacturer. Fragmented FFPE DNA was then subjected to whole genome amplification (WGA), and 2 L amplified DNA subjected to 45 cycles Q-PCR with primers designed by Primer 3 software (5) and described in Fig. 1B and a FAM-labeled probe that spanned the specific BCR-ABL1 breakpoint sequence. After successful Q-PCR (Fig. 1B) , the product was purified and sequenced using the reverse ABL1 primer. The fusion sequence in the mother's biopsy was verified as identical to that obtained from the pleural effusion of the child (Fig. 1C) .
The archived neonatal blood spot (Guthrie card) of the infant was screened for the clonotypic BCR-ABL1 genomic sequence using specific primers and as previously described for other fusion genes (6) . Three out of four blood spot slices were positive (Fig. 1D) , indicating that the cancer clone was present in the blood at birth.
Microsatellite Markers. Short tandem repeat (STR) microsatellite analysis of the DNA extracted from the jaw biopsy showed one predominant population (Ͼ95% of alleles) that did not correspond to the DNA profile obtained from the paternal sample (Fig. 2) . The STR profile shows that it shared one allele with the patient's germline DNA for all of the 15 STR markers studied which was different from the paternally-inherited alleles, demonstrating that the jaw tumor sample was of maternal origin (Ͼ95% maternal cells). STR analysis of the PE sample showed a mixture of alleles for most STR markers analyzed. These mixtures were identified either because of the presence of three different alleles in some markers, or because those markers with only two alleles presented an imbalance in the ratio of the peak areas (Fig. 2) . These findings were consistent with the presence of two genetically different cell populations in the PE specimenone maternal, one infant offspring (see Fig. 2 legend) .
HLA Analysis. Survival of maternal cells in the offspring presumably requires some form of immunological acceptance or tolerance of cells expressing foreign, non-inherited maternal MHC antigens. We serotyped samples from both parents for HLA-A, HLA-B, and DRB1, and both serotyped and genotyped the infant's normal blood and lymphoma cells. The result was that the BCR-ABL1-positive jaw tumor had selectively deleted or lost the HLA alleles that were not inherited by the daughter ( Table  1 ). The nature of this genetic lesion in the infant tumor cancer cells was further explored by high resolution SNP arrays. In the absence of normal germline maternal and infant DNA and only small quantities of degraded DNA from the maternal leukemia biopsy, we elected to analyze the infant lymphoma (jaw) sample for genome-wide lack of heterozygosity (LOH) in comparison with pooled normal control DNA. Table 2 summarizes the LOH analysis of the infant lymphoma. Recurrent deletions of IKZF1 and CDKN2A/B have previously been described in BCR-ABL1 ALL (7), as have deletions of EBF1 and RAG1/2 in B lineage childhood ALL (8) . In addition to these anticipated oncogenic or 'driver' deletions, we observed a large region of homozygosity on the short (p) arm of chromosome 6 including the whole HLA locus. This loss was accompanied by duplication of the other parental 6p region resulting in uniparental disomy. A large genomic deletion, including the HLA loci, therefore accounts for the loss of maternal HLA alleles.
Discussion
These data unambiguously mark the infant cancer as of maternal origin. Some 17 cases of probable metastasis to the fetus have now been recorded (1, 9, and current report), the first being in 1866, most being either melanoma (#6), a cancer with a notoriously metastatic proclivity, or leukemia/ lymphoma (#8). Given the phenotypic features described in these cases, it is likely that they were all, as presumed, of maternal origin rather than coincidental cancers. Genetic markers can unambiguously resolve cellular origins in this context. In three of the reported leukemia/lymphoma cases, the male infant bone marrow contained cells with an XX karyotype (1). Whilst these most probably do ref lect maternal leukemia/lymphoma cells, it cannot be excluded that they were non-malignant, normal maternal cells or infant male cells in which the Y chromosome was lost and X was duplicated. These are, individually, not rare events in leukemia (10, 11), although they seldom occur together in one clone. Other prior evidence for a maternal origin was the identification in a case of NK cell lymphoma of a specific chromosome translocation t(X;1)(q22;q12) in the maternal lymphoma and in three metaphases of the infant tumor (12) .
The rarity of materno-fetal transmission of cancer is a testimony to the efficacy of the placental barrier and perhaps to immunosurveillance. In the present case, an additional feature was the selective loss in the infant maternally-derived tumor cells of maternal HLA alleles that were not inherited by the infant (Tables 1 and 2 ). Loss of HLA would be expected to render the transmitted cancer cells immunologically inert (13) . HLA loci encoded cell surface proteins provide the major antigenic targets for allograft recognition and rejection, so it is likely that HLA deletion in this case contributed to successful transmission of the maternal leukemic cells. However, given the large size of the 6p deletion, it is possible that other gene losses could have contributed to the apparent lack of immuno-surveillance. Other unusual situations where cancer cell transmission occurs all appear to involve immunological invisibility (14) : inter-monozygotic twin transmission in utero (4), immunosuppressed recipients of cancer-infiltrated donor organs (15) , downregulated MHC antigen expression in venereal sarcoma in dogs (2) , and lack of MHC diversity in the Tasmanian devil (Sarcophilus harrisii) with transmissible facial tumors (16) . In a recent report (17) , loss of allorecognition of leukemic cell HLA by T cells, in a transplant context, also occurred by acquired uniparental disomy of chromosome 6p in the leukemic cells, as in the present study. It is possible that materno-feto transfer of cancer cells is more common than is reflected in the frequency of clinically diagnosed cases and that immuno-surveillance is the principal constraint.
Materials and Methods
Detection and Amplification of BCR-ABL1 Genomic Breakpoints. For detection and amplification of DNA breakpoints, ranging from 300 bp to 12 kbp the Expand Long Template PCR kit (Roche) with System 2 was used, with an annealing temperature of 64°C. To cover the BCR and ABL1 regions, within which breakpoints can occur, 21 BCR forward primers and 20 ABL1 reverse primers were used in multiplex, combining each BCR forward primer with 4 mixes of 5 ABL1 reverse primers.
The child's genomic breakpoint was initially amplified using BCR 3C F (GGGCTCATTTTCACTGGATGGAC) and the ABL1 D reverse primer mix, and upon split out PCR, a band was amplified with BCR 3C F and ABL1 1D R (AGC CAT AAC CAT TCT CCC AAG CA). The breakpoint was confirmed by reamplification and sequencing of the breakpoint in both the original and WGA amplified patient sample with BCR 3C F (GGGCTCATTTTCACTGGATGGAC), and a breakpoint specific ABL1 reverse primer (TTC AGG GGC CTT GGA TCA GAC TA) determined from sequencing the original cloned product. Forward and reverse primers for blood spot PCR were respectively (GATCCTTTTAAAT-AGGCAAG) and (GTAATGCCAAAAATAACACT).
Fifteen polymorphic STR markers were amplified in the paternal blood DNA and patient's PE and PB DNA samples using the Powerplex-16 system (Promega).
Genome Mapping Analysis. Mapping analysis was performed using 500 ng of tumor DNA from the infant lymphoma. DNA was prepared according to manufacturer's instructions using the GeneChip mapping 500K assay protocol for hybridization to GeneChip Mapping 250K Nsp and Sty arrays (Affymetrix). Briefly, genomic DNA was digested in parallel with restriction endonucleases NspI and StyI, ligated to an adaptor, and subjected to PCR amplification with adaptor-specific primers. The PCR products were digested with DNaseI and labeled with a biotinylated nucleotide analog. The labeled DNA fragments were hybridized to the microarray, stained by streptavidin-phycoerythrin conjugates, and washed using the Affymetrix Fluidics Station 450 then scanned with a GeneChip scanner 3000 7G.
Copy Number and LOH Analysis. SNP genotypes were obtained using Affymetrix GCOS software (version 1.4) to obtain raw feature intensity and Affymetrix GTYPE software (version 4.0) using the Dynamic Model algorithm with a call threshold of 0.33 to derive SNP genotypes. The sample was analyzed using CNAG 3.0 (http://plaza.umin.ac.jp/genome), comparing tumor sample with unpaired control DNA to determine copy number and LOH caused by imbalance (18) .
HLA Typing. Serotyping was by microdroplet lymphocyte cytotoxicity (19) . Genotyping was carried out using a reversed SSO HLA DNA typing method using fluorescent microspheres and a flow analyzer (20) .
